Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visual function improvement in patients with macroprolactinomas treated with bromocriptine.

R L Lesser1, J D Zheutlin, D Boghen

  • 1Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut 06510.

American Journal of Ophthalmology
|May 15, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of hydroxycinnamic acids on blue color expression of cyanidin derivatives and their metal chelates.

Food chemistry·2017
Same author

Spectral and colorimetric characteristics of metal chelates of acylated cyanidin derivatives.

Food chemistry·2016
Same author

Evaluating the role of metal ions in the bathochromic and hyperchromic responses of cyanidin derivatives in acidic and alkaline pH.

Food chemistry·2016
Same author

Diffuse unilateral subacute neuroretinitis masquerading as a white-dot syndrome.

The British journal of ophthalmology·2009
Same author

Recent advances in the management of adrenal incidentalomas.

Trends in endocrinology and metabolism: TEM·2008
Same author

Interpreting the multifocal visual evoked potential: the effects of refractive errors, cataracts, and fixation errors.

The British journal of ophthalmology·2005

Bromocriptine effectively treats visual field defects caused by prolactin-secreting macroadenomas, improving vision without surgery. Long-term, indefinite bromocriptine therapy is recommended, requiring ongoing monitoring.

Area of Science:

  • Neuro-oncology
  • Endocrinology
  • Ophthalmology

Background:

  • Prolactin-secreting macroadenomas can cause significant visual field defects.
  • Surgical or radiation treatments carry inherent risks and potential side effects.

Observation:

  • Eight patients with visual field defects secondary to prolactin-secreting macroadenomas were studied.
  • Patients received bromocriptine treatment, avoiding surgery or radiation.

Findings:

  • Bromocriptine treatment led to improved visual function in all studied patients.
  • No surgical or radiation interventions were required for these patients.

Implications:

  • Bromocriptine is recommended as a primary treatment for prolactin-secreting macroadenomas.

Related Experiment Videos

  • Effective bromocriptine therapy necessitates indefinite treatment and regular neuro-ophthalmologic, endocrine, and imaging follow-up.